Skip to content

史密斯内修

US · SNN #1382 按市值排名 上市于 1970
29.06 -0.03 -0.10%
实时 - 追踪5344个代码 - 心跳于359秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

低于合理价值
32.16 合理价值 ≈ 49.89 67.62
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为32.16-67.62。
  • 当前价格比按平均倍数计算的合理价值(49.89)低41.8%。

估值 各估值倍数与自身5年区间的对比

市净率 2.18 低于历史水平 第26百分位
5年平均 2.39 · 在Medical Devices中排名第53/125
市盈率 18.33 低于历史水平 第1百分位
5年平均 34.84 · 前瞻 15.23 · 在Medical Devices中排名第9/38
市销率 1.79 低于历史水平 第1百分位
5年平均 2.30 · 前瞻 1.70 · 在Medical Devices中排名第48/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
史密斯内修 (SNN) 12.16B 19.77 2.35 2.69%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值35.52 经济护城河Narrow 不确定性Low

当前股价低于晨星合理价值估算22.2%。

合理价值

Smith & Nephew PLC receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $35.52 per share, which is reinforced by this estimate's low uncertainty rating.

The company's valuation metrics bolster our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 6.5 lies in the bottom 20% compared with peers globally. Relative to the company's EBITDA, the enterprise value of the business is low, which contributes to our view that shares are cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 8.0%, for example, falls in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

经济护城河

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

史密斯内修 讨论区 0 条评论

发表评论